Since 1923, we have been focused on innovation and leadership in diabetes care. Today we have a broad portfolio of medicines.
Since the launch of our first pen needle in 1985, we have been committed to enhancing injection experience by putting technology in patient hands.
Access information on our products for rare bleeding disorders, growth hormone-related disorders, and women's health.
Chronic Weight Management
Find information on our treatment for chronic weight management in adults who are overweight with one weight-related comorbidity or obesity.
The following link used in conjunction with the FDA-approved product labeling may be used to determine U.S. patents associated with the corresponding U.S. marketed product.
Making a positive difference in people’s lives is at the heart of everything Novo Nordisk does – through groundbreaking science, sustained focus on the environment, and patient-centered care.
Our Media Relations team is ready to help you get all the information you need about Novo Nordisk.
Sales decreased by 2% in Danish kroner and increased by 4% in local currencies to USD 13.2 billion. • Sales of Victoza® increased by 6% to USD 2.9 billion (12% in local currencies). • Sales...
Bagsværd, Denmark, 31 October 2018 – Novo Nordisk today announced the expansion of its biopharm business with an agreement to acquire the US and Canadian rights to Macrilen™ (macimorelin),...
Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) approved an updated label for Saxenda® (liraglutide) injection 3 mg. The label now includes some data from the...
Sales decreased by 5% in Danish kroner and increased by 4% in local currencies to USD 8.8 billion. • Sales of Victoza® increased by 2% to USD 1.9 billion (12% in local currencies). • Sales of...
Visit the download center to download Novo Nordisk video and more
Sign up to receive our new alerts